The National Comprehensive Cancer Network (NCCN) [35] and European Society for Medical Oncology (ESMO) [36] guidelines for the treatment of metastatic or unresectable HER2-positive breast cancer recommend pertuzumab + trastuzumab and a taxane as first-line therapy (Table A1). This evidence concerns the gene ERBB2 and breast cancer.